American International Group Inc. bought a new position in Zymeworks Inc. (NYSE:ZYME – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,691 shares of the company’s stock, valued at approximately $222,000.
A number of other large investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its holdings in Zymeworks by 5.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 41,232 shares of the company’s stock worth $356,000 after purchasing an additional 2,187 shares in the last quarter. Quantbot Technologies LP raised its holdings in Zymeworks by 58.9% in the second quarter. Quantbot Technologies LP now owns 10,300 shares of the company’s stock worth $54,000 after purchasing an additional 3,818 shares in the last quarter. Stifel Financial Corp raised its holdings in Zymeworks by 10.1% in the first quarter. Stifel Financial Corp now owns 43,825 shares of the company’s stock worth $396,000 after purchasing an additional 4,025 shares in the last quarter. Bank of Montreal Can raised its holdings in Zymeworks by 19.8% in the first quarter. Bank of Montreal Can now owns 24,872 shares of the company’s stock worth $167,000 after purchasing an additional 4,103 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its holdings in Zymeworks by 7.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 61,966 shares of the company’s stock worth $535,000 after purchasing an additional 4,139 shares in the last quarter. 93.63% of the stock is currently owned by institutional investors.
Zymeworks Trading Up 2.1 %
Shares of NYSE:ZYME opened at $8.36 on Tuesday. Zymeworks Inc. has a twelve month low of $5.76 and a twelve month high of $10.80. The company’s 50 day moving average is $6.88 and its 200 day moving average is $7.69. The company has a market cap of $585.22 million, a PE ratio of 2.69 and a beta of 0.89.
Wall Street Analysts Forecast Growth
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
- Five stocks we like better than Zymeworks
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The most upgraded stocks in November have two things in common
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Monday.com rocked earnings like it’s the weekend
- P/E Ratio Calculation: How to Assess Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.